Halozyme to Participate at Upcoming Investor Conferences
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.
The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato la sua partecipazione a tre conferenze per investitori previste per settembre 2025. La CEO, Dr.ssa Helen Torley, e la VP Investor Relations, Tram Bui, rappresenteranno la societ脿.
Il calendario prevede interventi al Wells Fargo Healthcare Conference a Boston il 4 settembre, al Morgan Stanley Global Healthcare Conference a New York l'8 settembre e all'H.C. Wainwright Global Investment Conference a New York il 9 settembre. I webcast audio in diretta saranno disponibili sul sito di Halozyme con replay accessibile per 90 giorni.
Halozyme Therapeutics (NASDAQ: HALO) anunci贸 su participaci贸n en tres conferencias para inversores programadas para septiembre de 2025. La CEO, Dra. Helen Torley, y la VP de Relaciones con Inversores, Tram Bui, representar谩n a la compa帽铆a.
El calendario incluye presentaciones en la Wells Fargo Healthcare Conference en Boston el 4 de septiembre, en la Morgan Stanley Global Healthcare Conference en Nueva York el 8 de septiembre y en la H.C. Wainwright Global Investment Conference en Nueva York el 9 de septiembre. Habr谩 retransmisiones de audio en directo en la web de Halozyme con acceso a la repetici贸n durante 90 d铆as.
Halozyme Therapeutics (NASDAQ: HALO)電� 2025雲� 9鞗旍棎 臧滌禍霅橂姅 3臧滌潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 項爩 韱犿伌毽� 氚曥偓鞕� IR 雼措嫻 攵�靷灔 韸鸽灗 攵�鞚搓皜 須岇偓毳� 雽�響滍暕雼堧嫟.
鞚检爼鞚� 9鞗� 4鞚� 氤挫姢韯挫棎靹� 鞐措Μ電� Wells Fargo Healthcare Conference, 9鞗� 8鞚� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley Global Healthcare Conference, 9鞗� 9鞚� 雺挫殨鞐愳劀 鞐措Μ電� H.C. Wainwright Global Investment Conference鞐愳劀鞚� 氚滍憸毳� 韽暔頃╇媹雼�. 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼電� Halozyme 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅橂┌ 90鞚缄皠 鞛箔旆� 臧�電ロ暕雼堧嫟.
Halozyme Therapeutics (NASDAQ: HALO) a annonc茅 sa participation 脿 trois conf茅rences investisseurs pr茅vues en septembre 2025. La CEO, Dr Helen Torley, et la VP des relations investisseurs, Tram Bui, repr茅senteront la soci茅t茅.
Le programme inclut des pr茅sentations lors de la Wells Fargo Healthcare Conference 脿 Boston le 4 septembre, de la Morgan Stanley Global Healthcare Conference 脿 New York le 8 septembre et de la H.C. Wainwright Global Investment Conference 脿 New York le 9 septembre. Des webcasts audio en direct seront disponibles sur le site de Halozyme avec un acc猫s au replay pendant 90 jours.
Halozyme Therapeutics (NASDAQ: HALO) gab bekannt, dass das Unternehmen an drei Investorenkonferenzen im September 2025 teilnehmen wird. CEO Dr. Helen Torley und die VP Investor Relations, Tram Bui, werden die Firma vertreten.
Der Zeitplan umfasst Pr盲sentationen auf der Wells Fargo Healthcare Conference in Boston am 4. September, der Morgan Stanley Global Healthcare Conference in New York am 8. September und der H.C. Wainwright Global Investment Conference in New York am 9. September. Live-Audio-Webcasts sind auf der Halozyme-Website verf眉gbar und k枚nnen 90 Tage lang nachgeh枚rt werden.
- None.
- None.
Details on the Company's participation are as follows:
Event: | 2025 Wells Fargo Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Thursday, September 4, 2025 | |||
Presentation Time: | 10:30am PT / 1:30pm ET | |||
Location: | ||||
Event: | Morgan Stanley 23rd Annual Global Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Date: | Monday, September 8, 2025 | |||
Presentation Time: | 4:45am PT / 7:45am ET | |||
Location: | ||||
听 Event: | 听 H.C. Wainwright 27th Annual Global Investment Conference | |||
Format: | 1x1 Meetings | |||
Date: | Tuesday, September 9, 2025 | |||
Location: |
A live audio webcast of the presentations will be available in the 听of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE庐 drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE庐 technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex庐 and XYOSTED庐, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit 听and connect with us on LinkedIn and Twitter.
Contacts:
Tram听Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
Sydney Charlton
Teneo
917-972-8407
[email protected]
View original content to download multimedia:
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the Wells Fargo Healthcare Conference 2025?
What time is Halozyme's presentation at the Morgan Stanley Healthcare Conference 2025?
Who will represent Halozyme at the 2025 investor conferences?
How can investors access Halozyme's conference presentations?
